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ABSTRACT
The mechanisms involved in retinoic acid (RA)-
mediated regulation of the collagenase gene in a rabbit
synovial fibroblast cell line (HIG82) were investigated.
When HIG82 cells are cotransfected with expression
vectors containing cDNAs for retinoic acid receptor
(RAR) al, ,B2, or yl and collagenase promoter-driven
CAT reporter constructs, only RAR-yl represses basal
CAT expression upon RA treatment, while RAR-al, (32,
and -1 all suppress phorbol-induced CAT expression.
Thus, transcriptional regulation of collagenase by RA
is mediated by RARs in an RAR-type specific manner.
Using mutational and deletional analysis, we find that
interaction between elements within 182 bp
collagenase promoter plays an important role in this
process. In addition, cotreatment with RA results in a
decrease of phorbol-induced mRNA levels of fos andjun, and binding of nuclear proteins to an AP-1
oligonucleotide. Furthermore, RA-induced nuclear
protein(s) specifically bind to a 22 bp sequence (- 182
to - 161) of the collagena promoter. We propose that
RA-mediated regulation of the collagenase gene
depends on the availability and interaction of specific
RARs with multiple DNA elements within the promoter
and with transcription factors, including AP-1 related
proteins.
INTRODUCTION
The ability of retinoic acid (RA) and retinoic acid receptors
(RARs) to modulate gene expression and to influence
morphogenesis and deposition of the extracellular matrix has been
an important topic of recent research (1-3). Hence an
understanding of how RA modulates expression of the gene for
collagenase, the only enzyme able to degrade interstitial collagens
(type I,1I and E) at neutral pH (4), is central to our understanding
of connective tissue metabolism in normal development (5,6) and
in disease processes (7-9). Synthesis of collagenase is increased
by cytokines and growth factors, such as interleukin-1 (10-13),
tumor necrosis factor-a (14,15), and epidermal growth factor
(16), and these effects are mimicked by phorbol myristate acetate
(PMA) (11,13,17). Previous studies by a number of investigators
have shown that the regulation of collagenase synthesis by these
compounds occurs at the level of transcription (11,12,17), and
is mediated through the AP-1 binding site (11,18,19). More
recently, Auble and Brinckerhoff (20) demonstrated that the AP-1
site, alone, could not drive transcription of the collagenase gene
in PMA-stimulated fibroblasts, and that phorbol responsiveness
required cooperation among DNA sequences located within 127
bp of the collagenase promoter.
All-trans retinoic acid (RA) represses PMA-induced
collagenase synthesis by decreasing steady state levels of
collagenase mRNA (21,22) without affecting mRNA half-life
(21), indicating inhibition at the level of transcription. Recently,
three groups reported that RA inhibited expression of the genes
for collagenase (1 1,23) and a closely related enzyme, stromelysin
(24), through the AP-1 binding site, although there is no evidence
to suggest that RARs bind to the AP-1 site directly.
In this study, we demonstrate that suppression of basal
(constitutive) and induced collagenase gene expression by RA
is mediated in an RAR-type specific manner. Moreover,
regulation of collagenase gene expression by RA is more complex
than previously believed, and depends on the availability of
specific RARs, and their requirement for DNA elements within
the collagenase promoter.
MATERIALS AND METHODS
Cell culture
HIG82 cells were established by spontaneous immortalization of
a primary culture of rabbit synovial fibroblasts (25), and were
maintained in DMEM media supplemented with 10% fetal calf
serum. HIG82 cells remain contact-inhibited, do not grow in soft
agar, or form tumors in nude mice by seven months after
subcutaneous injection of 5 X i07 cells (C.E.Brinckerhoff,
unpublished observation).
Plasmids
The chimeric DNA constructs used in this study are shown in
Fig. lA. The fusion of 182 bp or 102 bp of the rabbit collagenase
promoter into the unique HindIll site of pSVOCAT (26), and
the ability of these inserted fragments to drive transcription of
the promoterless bacterial gene chloramphenicol acetyltransferase
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(CAT) has been described (20). Two mutations were generated
in the 182 bp wild type sequence of collagenase 5' flanking DNA
by substitution mutagenesis (20). The cDNAs encoding mouse
RAR-AO (2.1 kb), ,( (1.95 kb) and -y (2.0 kb) have been inserted
in the sense orientation into the EcoRI site of pSG5 expression
vector driven by SV40 early promoter (27), and mouse RAR--y
was also inserted in the reversed orientation (rRAR--y) as a
control. Multiple isoforms ofRAR-a, f3 and -y have been cloned,
and isoforms 1 and 2 are the predominant forms of these receptors
(28-30). The RAR expression vectors used in this study were
subsequently named as RAR-cil, ,32 and 'yl (28-30).
Transfection and CAT assay
Transient transfection and CAT assay were performed as
previously described (20). Briefly, equal amounts of DNA (2.5Ag
DNA per 60 mm plate, unless otherwise indicated) containing
the chimeric CAT construct and RAR expression vector were
cotransfected into HIG82 cells by the calcium phosphate
coprecipitation method, followed by 10% glycerol shock for 3
minutes. After overnight recovery, cells were cultured in DMEM
plus 0.2% lactalbumin hydrolysate (LH) alone, or treated with
10-6M RA for 26h, 10-8M PMA for 24h, or 10-6M RA plus
10-8M PMA 24h after a 2h pretreatment with RA. Cell extracts
were prepared by the freeze-thaw method, and protein
concentrations in the cell extracts were determined by Bradford
assay (Bio-Rad). Five yg protein per sample was incubated with
0.25 tCi 14C-chloramphenicol in reaction buffer (1.4mM Acetyl
CoA, 14mM Tris-Cl, pH 7.8, 3.5% glycerol) for 2h, the reaction
products were resolved by thin-layer chromatography (TLC) and
autoradiography, and were quantitated by scintillation counting
of the TLC plate. Acetylation of 14C-chloramphenicol in extracts
from untreated and treated cells was in the linear range of the
assay (0.5% to 30% conversion). Results of CAT assays were
normalized to the percentage acetylation of 14C-chloramphenicol
in extracts from untreated cells within the same transfection
group. Student's paired t-test was used for statistical analysis.
Hirt's assay
Plasmid DNA from transfected cells was prepared as described
(31). DNA extracted from 5 x 105 cells per transfection was
denatured and slot-blotted onto GeneScreen Plus membrane
(NEN). The membrane was hybridized with denatured
[a-32P]dCTP-labeled probes specifically for CAT, RAR-a, or
-y for 20h at 42°C, then washed with 0.2xSSC, 0.25% SDS
twice at room temperature for 10 minutes, and twice at 56°C
for 30 minutes. The membranes were exposed to a X-ray film
(Kodak) overnight. Using this assay, we found that RAR-ac1,
(32, -yl or rRAR--yl were cotransfected into HIG82 cells without
altering the transfection efficiency ofpCCAT182, although a low
level of cross-hybridization between RARs and their parent vector
pSG5 was noticed (Fig. lB).
RNAse protection analysis
RNAse protection analysis was performed as described (20).
Briefly, total RNA from transfected cells was isolated by phenol
extraction and isopropanol precipitation. Forty yg RNA was
hybridized to a riboprobe (2 x 106cpm probe/sample) obtained
by T7 RNA polymerase (Promega) transcription of an NcoI-
linearized, pGEM3-derived plasmid (Promega) containing 380
bp collagenase 5' flanking DNA fused to 251 bp of the CAT
gene. The specific activity of the riboprobe was lI8DPM4Lg
DNA. The reaction products were resolved on a 5% denaturing
polyacrylamide gel. The gel was dried on a piece of filter paper,
and then exposed to X-ray film overnight.
Northern analysis
Total RNA from HIG82 cells was prepared by the guanidinium
thiocyanate-CsCl method (32). Twenty jig RNA per sample was
electrophoresed on a 1% formaldehyde agarose gel. The gel was
stained with ethidium bromide ( lg/ml) for loading quantitation,
and then transferred to GeneScreen Plus membrane. The
membrane was hybridized with denatured [a-32P]dCTP-labeled
probe for 20h at 56°C, then washed with 0.2 x SSC, 0.25% SDS
twice at room temperature for 10 minutes, and twice at 56°C
for 30 minutes. Hybridization with glyceraldehyde phosphate
dehydrogenase (GAPDH) was also used as a control.
cDNA probes
Full length cDNA inserts of RAR-a 1, -yl, a 900 bp cDNA
fragment of RAR-(32 (EcoRI) (27), a 414 bp fragment of CAT
(EcoRI-Scal) (26), a 630 bp fragment for collagenase (EcoRI-
HaeIll) (33), full length cDNA inserts of c-jun (ATCC), c-fos
(ATCC), and a 550 bp cDNA fragment of GAPDH (Hind III-
Xba I, ATCC) were used as probes in Hirt's assay and Northern
analysis. Probes were labeled with [a-32P]dCTP (3000 Ci/mM,
NEN) by random priming (Pharmacia). The specific activity of
the probes was 21 x 106 DPM/ng DNA, and the probes were
used at a final concentration of 106cpm probe per ml
hybridization buffer in Hirt's assay and Northern analysis.
Preparation of nuclear extracts and mobility shift assay
Nuclear extracts were prepared according to Lee et al. (34) with
the following modifications: Cells swollen in hypotonic solution
at 4°C were passed through a 25 gauge needle 10 times to disrupt
cell membranes. Isolated nuclei were extracted for 30 minutes
at 4°C in extraction buffer (1OmM Hepes pH 7.9, 12% glycerol,
8mM MgCl2, 500mM KCI, 0.1mM EDTA, 0.1mM PMSF,
0.25mM DTT), then dialyzed for lh against dialysis buffer
(IOmM Hepes pH 7.9, 12% glycerol, lOOmM KCI, O.1mM
EDTA, 0. lmM PMSF, 0.25mM DTT). Nuclear extracts (3 - 10
Ag protein/sample) were incubated with 40,000 cpm[y-32P]ATP-labeled double-stranded oligonucleotides (specific
activity 2 xlO6DPM/pm 5'-end oligo) in binding buffer
(12mM Hepes pH 7.9, 4mM Tris-HCl pH7.9, 12% glycerol,
60mM KCI, 1mM EDTA, litg poly dI-dC) for 15 minutes at
30°C. Products were resolved by electrophoresis on a 5% non-
denaturing polyacrylamide gel. The gel was dried on a piece of
filter paper, and then exposed to a X-ray film overnight.
RESULTS
To understand the mechanisms involved in transcriptional
regulation of the collagenase gene, we used the rabbit synovial
fibroblast cell line, HIG82, to examine pSVOCAT expression
driven by the rabbit collagenase promoter. In keeping with our
previous studies in primary cultures of synovial fibroblasts
(17,20), we find that the expression of promoter-less pSVOCAT
in HIG82 cells is not affected by either RA or PMA treatment
(data not shown). The levels of acetylation of 14C-
chloramphenicol in extracts from HIG82 cells transfected with
the collagenase promoter driven CAT constructs range from
1-5%, and increase to as much as 20-30% upon PMA
treatment.
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Fig. 1. A. Chimeric DNA constructs containing up to 182 bp of the rabbit collagenase promoter linked to pSVOCAT. The plasmids are designated 'pCCAT' followed
by a number which indicates the size of the rabbit collagenase 5' flanking DNA (in bp) inserted. TTCA is a PMA inducible element, TGAGTCAC is the AP-I
consensus sequence. Two mutations were generated from the 182 bp wild type sequence of collagenase 5' flanking DNA. Mutated bases are underlined. B. Assessment
of transfection efficiency by Hirt's assay. The pCCAT 182 construct was transiently transfected into HIG82 cells. Plasmid DNAs cotransfected with pCCAT182
in equal amounts are indicated. Plasmid pUC19 is a nonrelated plasmid used as a control. After overnight recovery, cells were cultured in DMEM medium supplemented
with 2% LH for 24h. Hirt's assay was performed as described in Materials and Methods.
Suppression of constitutive collagenase gene expression by RA
is mediated through RAR-,y
We noticed that RA only slightly suppressed collagenase
promoter-driven CAT expression in primary rabbit fibroblasts
and HIG82 cells, although in the same cells the endogenous
collagenase mRNA was markedly decreased (17). A similar
finding has been reported for induction of laminin Bi gene
expression by RA in F9 mouse cells, where cotransfection of
exogenous human RAR-cx, 13, or 'y was required to elucidate the
RA response (35). To test whether the failure of RA to suppress
collagenase promoter-driven CAT expression in HIG82 cells is
due to the limited availability of RARs, we transiently
cotransfected pCCAT182 or pCCAT102 into HIG82 cells with
expression vectors containing cDNAs for mouse RAR-c 1, ,32
or yl at a 1:1 molar ratio (Table 1). For both constructs, only
cotransfection of RAR-'y 1, in the presence of RA, inhibits basal
CAT expression. Neither RAR-'yl in the reversed orientation
(non-sense), nor RAR-clI and 132 changes basal CAT expression
significantly (p> 0.05). These data demonstrate that RA inhibits
constitutive collagenase gene expression in an RAR-type specific
manner.
Sequences within 182 bp of the collagenase promoter are
required for RA-mediated suppression
We also examined the regulation of PMA-induced collagenase
transcription by RA using the pCCAT182 construct (Fig.2A).
Treatment with PMA increases CAT activity by four fold, and
cotreatment with RA does not antagonize this induction. When
the RAR-'yl expression vector is cotransfected with pCCAT 182,
the induction of CAT activity by PMA is similar to that seen
in the cells without cotransfection. However, cotreatment with
RA decreases the PMA-induced CAT activity by 60%. This
antagonism is not observed when RAR-7y1 in the reversed
orientation (non-sense) is cotransfected with pCCAT182. Co-
transfection of RAR-cxl or 132 with pCCAT182 also results in
a decrease of PMA-induced CAT activity upon cotreatment with
RA, which is not seen with cotransfection of parent vector pSG5
without the RAR insert (Table 2). These data suggest that
repression of PMA-induced collagenase gene expression can be
mediated by all three types ofRAR (<x, and -y), and only RAR-'y
inhibits constitutive collagenase gene expression upon RA
treatment.
Table 1. Repression of basal CAT activity by RAR-'y upon RA treatment
Cotransfection pSG5 RAR-a RAR-,B RAR-^y rRAR--y
pCCAT182 0.89±0.11 0.98+0.10 0.94+0.11 0.33+0.06 0.8740.09
pCCAT102 1.100.07 1.00±0.07 0.95±0.03 0.37±0.05 1.21 ±0.12
The pCCAT182 or pCCAT102 constructs were transiently cotransfected into
HIG82 cells with RAR expression vectors or the parent vector without RAR inserts
(pSG5) at 1: 1 molar ratio. Cells were then treated with 10 6M RA for 26h. Five
ag protein from each sample was used for CAT assay. The values of each construct
represent percentage acetylation of 14C-choloramphenicol in extracts from RA-
treated cells divided by percentage acetylation of 14C-choloramphenicol in
extracts from untreated cells. Results shown are the mean of four independent
transfections ± S.E.
Table 2. Regulation of CAT activity by RARs upon RA plus PMA treatment
Cotransfection pSG5 RAR-ca RAR-, RAR-^y rRAR--y
pCCAT182 1.00±0.14 0.68±0.06 0.47±0.04 0.42±0.05 1.13±0.09
pCCAT102 3.15+0.27 1.01 ±0.10 1.04+0.12 0.93+0.05 3.28±0.29
The pCCAT182 or pCCAT102 constructs were transiently cotransfected into
HIG82 cells with RAR expression vectors or the parent vector without RAR inserts
(pSG5) at 1:1 molar ratio. Cells were then treated with PMA or RA plus PMA.
Five 1&g protein from each sample was used for CAT assay. The values of each
construct represent percentage acetylation of 14C-choloramphenicol in extracts
from cells cotreated with RA plus PMA divided by percentage acetylation of 14C-
choloramphenicol in extracts from cells treated with PMA only. Results shown
are the mean of four independent transfections ± S.E.
Previous studies by other investigators on the regulation of
metalloproteinase genes (collagenase and stromelysin) by RA
have focused mainly on the AP-1 site (11,23,24). However,
transfection of pCCAT102, which contains an intact AP-1
sequence in its native promoter configuration, results in a loss
of CAT induction upon PMA treatment (Fig.2B), a finding in
agreement with our earlier studies in primary rabbit fibroblasts
(20). Interestingly, the combination of RA and PMA treatment
results in a synergistic enhancement of CAT expression.
Cotransfection of RAR--yl abolishes this enhancement, while
cotransfection of RAR--y in the reversed orientation does not
(Fig.2B). Cotransfection of RAR-al or ,B2 with pCCAT102 also
diminishes this synergism (Table 2). These findings suggest that
sequences between -182 to -102 bp of collagenase promoter
are able to repress this enhanced CAT activity.
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Fig. 2. RAR-y inhibits collagenase promoter-driven CAT expression. The
pCCAT182 (A) or pCCAT102 (B) were cotransfected with RAR--y1 or rRAR-
ylI into HIG82 cells. Cells were then treated with PMA or RA plus PMA. CAT
assays were carried out as described in Materials and Methods. Acetylation of
14C-choloramphenicol in extracts from untrated cells was in the range of 2-5%
(pCCAT182), or 1-2% (pCCAT102). Results shown are the mean of four
independent transfections + S.E. A value of 1 represents the levels ofCAT activity
in extracts from untreated cells.
To further localize the promoter region for this response, we
examined the expression of mutant TTCA construct (four base
pair mutation at -109 to -106 bp in wild type pCCAT 182, see
Fig. lA). Previously, we have shown that this TTCA element
was necessary for induction of collagenase gene expression by
PMA in primary rabbit fibroblasts (20). Now, we find that this
mutation also results in a loss of PMA-inducibility in HIG82 cells
(Fig.3A). As with the pCCAT102 construct, in the presence of
both RA and PMA, a synergistic enhancement of CAT activity
is observed (Fig.3A), although either RA or PMA alone does
not increase CAT activity significantly (P> 0.05). Cotransfection
of RAR--yl abolishes this synergism completely (Fig.3A),
whereas cotransfection of RAR-'yl in the reversed orientation
does not greatly change this enhancement (Fig.3A). These results
imply that the TTCA element is required for suppression of this
enhancement by RA and PMA.
We also examined the role of AP-1 site using a construct
containing a single base pair mutation in wild type pCCAT 182,
which is known to prevent binding of the Fos/Jun heterodimer
(18, see Fig. lA). As expected, this construct results in a loss
of PMA inducibility in HIG82 cells (Fig.3B). Surprisingly, CAT
activity of this construct increases upon RA treatment (p < 0.05),
and cotransfection with RAR-ca1 or 132 fails to abrogate this
increase (data not shown). Only cotransfection with RAR-'yl in
the sense orientation brings the CAT activity back down to the
control level (Fig.3B), thus indicating that RAR-'yl can exert its
effects in the absence of an intact AP-1 site.
To ensure that the CAT activity measured in the above
experiments (Fig.2) reflected transcriptional regulation, we
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Fig. 3. Mutational analysis of pCCAT182 construct. The mutant TTCA (A) or
mutant AP- I (B) was cotransfected with RAR--y I or rRAR--y I into HIG82 cells.
Treatments and assays were carried out as described in Materials and Methods.
Acetylation of 14C-choloramphenicol in extracts from untreated cells was in the
range of 1-2%. Results shown are the mean of four independent transfections
± S.E. A value of I represents the levels ofCAT activity in extracts from untreated
cells.
examined the steady state level of CAT mRNA in transfected
HIG82 cells by RNAse protection analysis (Fig.4A). Induction
of CAT mRNA by PMA is greater in the pCCAT182 construct
than that in pCCAT102. RA, in combination with PMA, further
increases the CAT mRNA in cells transfected with pCCAT102,
but reduces PMA-induced CAT mRNA in cells transfected with
pCCAT182. Thus, levels of CAT mRNA parallel the levels of
CAT protein activity presented in Fig.2. In addition, the
modulation of endogenous collagenase mRNA by RA and PMA
is similar in both transfection groups (pCCAT182 vs pCCAT102)
as determined by Northern analysis (Fig.4B). Furthermore, in
agreement with our previous findings (17), collagenase protein
in culture media of these cells is decreased by RA as determined
by Western analysis and by a 14C-collagen fibril assay (data not
shown). Thus, the disparate regulation of endogenous
gene/pCCAT182 vs pCCAT102 by RA suggests the presence
of RA-response elements within 182 bp of collagenase promoter.
Roles of Fos/Jun and the AP-1 binding site in RA-mediated
collagenase gene regulation
Since previous studies showed that negative regulation of
collagenase gene expression by RA was mediated through the
AP-l site which binds Fos/Jun (11, 23), we also examined the
roles of AP-1 site and fos/jun in our system. Using Northern
analysis, we find that RA decreases the PMA-induced mRNA
levels of c-fos and c-jun. This inhibition of fos/jun mRNAs by
RA continues for at least 24h (Fig.5).
The decrease of AP-l related proteins by RA is supported by
mobility shift experiments. A 33mer, representing the sequence
from -88 to -56 of the collagenase promoter containing the
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Fig. 4. Regulation of CAT mRNA (A) and endogenous collagenase mRNA (B)
by RA and PMA. HIG82 cells were transfected with pCCAT102 or pCCAT182
(10 sg/ 100 mm plate). Cells were cultured in DMEM plus 2% LH (C), or treated
for 24h with 10-6M RA (R), 10-8M PMA (P), or 10-6M RA plus 10-8M
PMA (RP). (A) RNAse protection analysis. Forty lAg total RNA per sample was
used. The protected band is indicated by the arrow. A reaction containing 20ug
RNA from PMA-treated cells transfected with pCCAT182 is indicated as 1/2
RNA. (B) Northern analysis. Four lAg total RNA per sample (same RNA as usedin Fig.4A) was used. Specific mRNA hybridization to 32P-labeled cDNAs for
collagenase or GAPDH is indicated.
AP-1 site, was used as the probe in the experiment shown in
Fig.6A. The nuclear extracts derived from PMA-treated cells
bind specifically to this AP-1 oligonucleotide (33mer) as expected,
and this binding is competed by a 100 fold molar excess of self,
but not by the 42mer oligonucleotide (-182 to -141 of the
collagenase promoter). However, when extracts from cells treated
with PMA plus RA are used, the amount of complex formed
decreases markedly. Further, a 10 fold molar excess of self and
a 100 fold excess of the 42mer are able to compete this complex
formation. These results suggest that RA decreases the amount
and/or affinity of protein binding to an AP-1 oligonucleotide,
and that RA-induced nuclear proteins may bind to sequences
within the 42mer and to PMA-induced proteins which bind to
an AP-1 oligonucleotide.
The possibility that RA-induced proteins bind to both
collagenase promoter sequences and AP-1 related proteins is
further illustrated in the mobility shift experiment shown in
Fig.6B. The 22mer (-182 to -161 of the collagenase promoter)
is used as a probe in this representative experiment. Three
complexes are formed with nuclear extracts from cells treated
with RA, while little complex formation is observed with extracts
from PMA-treated cells. All three complexes are competed by
100 fold excess of self, while two complexes are competed
partially by 100 fold excess of the AP-1 oligonucleotide,
suggesting that these two complexes may contain AP-1 related
proteins.
Fig. 5. Inhibition of c-fos, c-jun mRNAs by RA. HIG82 cells were treated with
10-6M RA (R), 10-8M PMA (P), or 10-6M RA plus 10-8M PMA (RP) for
12h or 24h. Total RNA was prepared by the guanidinium thiocyanate-CsCI method.
Twenty 1tg RNA per sample was used. Specific mRNA hybridization to 32p
labeled cDNAs for c-fos, c-jun or GAPDH is indicated.
DISCUSSION
Differential regulation of the collagenase gene by RA
Our study demonstrates that RA-mediated suppression of CAT
expression driven by the collagenase promoter is dependent on
the availability of functional RARs, and that RAR-a, ( and -y
differentially regulate collagenase transcription. Upon RA
treatment, only RAR-'yl represses the basal CAT expression
driven by the collagenase promoter (Table 1), whereas all three
RARs (al, (32 and -yl) suppress PMA-induced CAT expression
driven by 182 bp collagenase 5'-flanking DNA (Fig.2A, Table
2). Thus, suppression of basal and induced collagenase gene
expression by RA is mediated in trans by RAR-type specific
mechanisms. These results differ with those reported by Schule
et al. (23) who found that all three RARs (a, a and -y) repressed
basal/constitutive collagenase promoter expression. However,
their study was carried out in HeLa cells with a 1200 bp promoter
construct, while we used normal fibroblasts and a 182 bp
promoter construct. The difference between these two studies
may be due to cell-type specific gene regulation, although the
size of promoter constructs cannot be ruled out.
It has been reported that RAR--y is predominantly expressed
in embryonic tissue and in adult tissues such as skin and lung,
whereas RAR-a and (3 are expressed in a variety of tissues (27).
We find that only RAR-'y mRNA is detectable by Northern
analysis in untreated HIG82 cells. However, the mRNAs for all
three RARs are increased markedly within 3h of RA treatment
(unpublished observation). Since RARs play distinct roles during
cell differentiation (3,36,37) and morphogenesis (3,28,38-40),
it is conceivable that RAR-specific modulation of collagenase
transcription may be important during normal development and
in disease processes where the modeling and remodeling of
connective tissue is involved.
Interaction of AP-1 related proteins and RA-induced proteins
with 182 bp of collagenase promoter is involved in RA-
mediated collagenase gene regulation
The importance of the AP-1 binding site in RA-mediated negative
regulation of metalloproteinase genes (collagenase and
stromelysin) has been demonstrated (11,23,24), and our data
support a role for AP-1 in RA-mediated repression of collagenase.
We also find that RA decreases the steady-state levels of both
c-fos and c-jun mRNAs (Fig.5), and this decrease in AP-1 related
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Fig. 6. Specific complex fornation between nuclear proteins and radiolabeled fragments of the rabbit collagenase promoter. HIG82 cells were cultured in DMEM
plus 2% LH (CON) or treated with 10 8M PMA, 106M RA, or PMA+RA for 2h (A), or 6h (B). A. Specific complexes formation with the AP-1 oligoprobe.
The oligoprobe represents sequence from -88 to -56 of the collagenase promoter containing the AP-I consensus (underlined) 5'-AGCTTCTAGAAAGCATGAGT-
CACACAAGCCCTCAGCTG-3'. Three zg nuclear extract proteins were reacted with double stranded oligoprobe alone (NO COMP) or in the presence of lOx
or 100xmolar excess of unlabeled competitors of self (AP-1) or '42mer', a 42 bp fragment from - 182 to - 141 of the collagenase promoter (5'-TCATGAAATTGC-
AACACCAAGCTAACCCAAAAAATCTGCCG-3'). B. Specific complex formation with a 22 bp double-stranded oligoprobe (22mer) from - 182 to - 161 of the
rabbit collagenase promoter (5'-TCATGAAATTGCAACACCAAGC-3'). Ten itg nuclear extract proteins were reacted with oligoprobe either alone (NO COMP)
or in the presence of 100xmolar excess of unlabeled competitors of self or AP-1 oligo as described above.
proteins is supported by the mobility shift experiment shown in
Fig.6A. These mobility shift experiments (Fig.6A,6B) also
provide evidence that RA-induced nuclear proteins can bind to
the nucleotides between -182 and -141 bp of the collagenase
promoter, and compete binding of nuclear proteins to an AP-1
oligonucleotide. These results illustrate the importance of
cooperation between DNA elements within the collagenase
promoter. The possibility that RA-induced protein(s) could form
complexes with AP-1 related protein(s) is supported by in vitro
experiments in which the binding of RAR-cx to Jun protein can
reduce the binding of Jun to the AP-1 site (23). Studies with
glucocorticoid receptors have also demonstrated that negative
gene regulation mediated by the glucocorticoid receptor is due
to the direct binding of the receptor to the c-Jun protein and to
the AP-1 site (41-44). All these studies suggest a potential
mechanism of repression via protein-protein interaction in
addition to protein-DNA interaction.
Cooperation of DNA elements within colagenase promoter
and availability of specific RARs play a central role in RA-
mediated collagenase gene regulation
Several retinoic acid response elements (RARE) have been
reported, and most of them involve palindomes or direct repeats
(3,45-48). Although we do not find any elements within 182
bp collagenase promoter identical to the reported RAREs
(3,45 -48), we demonstrate that interaction between DNA
elements within the promoter contributes substantially to the
ability of RA and PMA to modulate coilagenase gene expression.
Sequences within 182 bp of the collagenase 5'-flanking DNA
are required to repress both constitutive and PMA-induced gene
expression by RA in HIG82 cells. The presence of both the TT-
CA element and the AP-l consensus sequence are neccessary
for PMA-induced collagenase transcription (20, Fig.2B,3A,3B).
The TTCA element also plays an important role in RA-mediated
suppression, since mutation or deletion of this element gives a
synergistic enhancement of CAT expression in the presence of
RA and PMA (Fig.2B,3A). The fact that cotransfection ofRAR-
cal, (32, and -yl can antagonize this enhancement (Fig.2B,3A,
Table 2) suggests that it may be mediated by RA-induced factor(s)
that are distinct from the transfected RARs. For example,
retinoid X receptor (RXR) can form heterodimers with RARs,
then enhance RAR response by increasing ligand sensitivity and
DNA binding (49-52). On the other hand, RXR could also act
as a competitor ofRAR by binding to the same response element
(53). Antagonism between RAR-,B and RAR--yl or different
isoforms of RAR-'y has also been reported (54). In combination
with studies reported by others, our results suggest that
availability and interaction of these receptors with DNA elements
within the collagenase promoter play a central role in mediating
the retinoid response.
q q
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In summary, our data suggest that sequences in addition to the
AP-1 site play a role in mediating RA repression. Further, the
sequences associated with RA repression are also involved in
PMA induction. Mutation or deletion of these PMA-response
elements abolishes RA repression, and even confers a positive
regulation by RA. This positive regulation can be abrogated by
cotransfection of RARs, suggesting a quantitative contribution
of these receptors in mediating RA effects. Thus, transcriptional
regulation of collagenase is likely to depend on the availability
of specific RARs and other RA-induced proteins, as well as
interactions between DNA elements and various transcriptional
factors, including Fos and Jun.
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